Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ETTX

Entasis Therapeutics (ETTX) Stock Price, News & Analysis

Entasis Therapeutics logo

About Entasis Therapeutics Stock (NASDAQ:ETTX)

Key Stats

Today's Range
$2.19
$2.19
50-Day Range
$2.18
$2.20
52-Week Range
$1.40
$3.88
Volume
800 shs
Average Volume
239,104 shs
Market Capitalization
$104.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Receive ETTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ETTX Stock News Headlines

Election warning coming true…
If you missed it, my emergency election broadcast is now available - watch it before it's too late.
See More Headlines

ETTX Stock Analysis - Frequently Asked Questions

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26).

Entasis Therapeutics (ETTX) raised $75 million in an initial public offering on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Entasis Therapeutics investors own include Sorrento Therapeutics (SRNE), VYNE Therapeutics (VYNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), CymaBay Therapeutics (CBAY), Dynavax Technologies (DVAX) and Pfizer (PFE).

Company Calendar

Last Earnings
11/04/2021
Today
11/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ETTX
Fax
N/A
Employees
51
Year Founded
N/A

Profitability

Net Income
$-47,140,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7 million
Book Value
$0.66 per share

Miscellaneous

Free Float
44,742,000
Market Cap
$104.80 million
Optionable
Not Optionable
Beta
1.33
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ETTX) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners